pdce2 expression plasmid Search Results


synthetic pdc-e2 166–181 peptide  (GenScript corporation)
90
GenScript corporation synthetic pdc-e2 166–181 peptide
Mitochondrial autoantigen-based pMHCII-NPs expand cognate TR1 cells. a Percentages of tetramer+ CD4+ cells in blood of NOD vs. NOD. c3c4 mice vs. age (4 and 5 mice/strain, respectively). b Percentage of tetramer+ CD4+ cells in blood of pMHCII-NP-treated NOD. c3c4 vs. untreated or control NP-treated NOD or NOD. c3c4 mice. Data correspond to: 2–5 untreated NOD mice (1 experiment); 2–5 untreated and 15 Cys-NP-treated NOD. c3c4 mice and 18 PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice (5 experiments); three untreated and five PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice (2 experiments); and 3–5 untreated and 3–5 <t>BDC2.5mi/IA</t> g7 -NP-treated NOD. c3c4 mice (2 experiments). c Percentages of tetramer+CD4+ cells in various organs from the mice in ( c ) at the end of therapy. d Percentages of tetramer+CD4+ cells in lymphoid organs and liver of NOD. c3c4 mice treated for 9 weeks with PDC 82–96 /IA g7 -NPs or PDC 166–181 /IA g7 -NPs. Data correspond to four untreated and three PDC 166–181 /IA g7 -NP treated, and six untreated and eight PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice. e Percentages of tetramer+CD4+ cells in liver and various lymphoid organs in the NOD. c3c4 mice treated with BDC2.5mi/IA g7 -NPs from panel b . f Expression of TR1 markers by PCLN tetramer+CD4+ cells. g Cytokine profile of sorted splenic tetramer+CD4+ and tetramer–CD4+ cells upon stimulation with peptide-pulsed DCs. Data correspond to four PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice from three experiments. Data are represented as mean ± SEM. P values were calculated via two-way ANOVA ( a and b ) or Mann–Whitney U ( c – e )
Synthetic Pdc E2 166–181 Peptide, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdce2+expression+plasmid/n+terminally+flag+tagged+pdce2+expression+plasmid/pmc06517389-222-4-9
Average 90 stars, based on 1 article reviews
synthetic pdc-e2 166–181 peptide - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Mitochondrial autoantigen-based pMHCII-NPs expand cognate TR1 cells. a Percentages of tetramer+ CD4+ cells in blood of NOD vs. NOD. c3c4 mice vs. age (4 and 5 mice/strain, respectively). b Percentage of tetramer+ CD4+ cells in blood of pMHCII-NP-treated NOD. c3c4 vs. untreated or control NP-treated NOD or NOD. c3c4 mice. Data correspond to: 2–5 untreated NOD mice (1 experiment); 2–5 untreated and 15 Cys-NP-treated NOD. c3c4 mice and 18 PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice (5 experiments); three untreated and five PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice (2 experiments); and 3–5 untreated and 3–5 BDC2.5mi/IA g7 -NP-treated NOD. c3c4 mice (2 experiments). c Percentages of tetramer+CD4+ cells in various organs from the mice in ( c ) at the end of therapy. d Percentages of tetramer+CD4+ cells in lymphoid organs and liver of NOD. c3c4 mice treated for 9 weeks with PDC 82–96 /IA g7 -NPs or PDC 166–181 /IA g7 -NPs. Data correspond to four untreated and three PDC 166–181 /IA g7 -NP treated, and six untreated and eight PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice. e Percentages of tetramer+CD4+ cells in liver and various lymphoid organs in the NOD. c3c4 mice treated with BDC2.5mi/IA g7 -NPs from panel b . f Expression of TR1 markers by PCLN tetramer+CD4+ cells. g Cytokine profile of sorted splenic tetramer+CD4+ and tetramer–CD4+ cells upon stimulation with peptide-pulsed DCs. Data correspond to four PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice from three experiments. Data are represented as mean ± SEM. P values were calculated via two-way ANOVA ( a and b ) or Mann–Whitney U ( c – e )

Journal: Nature Communications

Article Title: Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

doi: 10.1038/s41467-019-09893-5

Figure Lengend Snippet: Mitochondrial autoantigen-based pMHCII-NPs expand cognate TR1 cells. a Percentages of tetramer+ CD4+ cells in blood of NOD vs. NOD. c3c4 mice vs. age (4 and 5 mice/strain, respectively). b Percentage of tetramer+ CD4+ cells in blood of pMHCII-NP-treated NOD. c3c4 vs. untreated or control NP-treated NOD or NOD. c3c4 mice. Data correspond to: 2–5 untreated NOD mice (1 experiment); 2–5 untreated and 15 Cys-NP-treated NOD. c3c4 mice and 18 PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice (5 experiments); three untreated and five PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice (2 experiments); and 3–5 untreated and 3–5 BDC2.5mi/IA g7 -NP-treated NOD. c3c4 mice (2 experiments). c Percentages of tetramer+CD4+ cells in various organs from the mice in ( c ) at the end of therapy. d Percentages of tetramer+CD4+ cells in lymphoid organs and liver of NOD. c3c4 mice treated for 9 weeks with PDC 82–96 /IA g7 -NPs or PDC 166–181 /IA g7 -NPs. Data correspond to four untreated and three PDC 166–181 /IA g7 -NP treated, and six untreated and eight PDC 82–96 /IA g7 -NP-treated NOD. c3c4 mice. e Percentages of tetramer+CD4+ cells in liver and various lymphoid organs in the NOD. c3c4 mice treated with BDC2.5mi/IA g7 -NPs from panel b . f Expression of TR1 markers by PCLN tetramer+CD4+ cells. g Cytokine profile of sorted splenic tetramer+CD4+ and tetramer–CD4+ cells upon stimulation with peptide-pulsed DCs. Data correspond to four PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice from three experiments. Data are represented as mean ± SEM. P values were calculated via two-way ANOVA ( a and b ) or Mann–Whitney U ( c – e )

Article Snippet: Synthetic PDC-E2 166–181 and 2.5mi peptides were purchased from Genscript (Piscataway, NJ).

Techniques: Control, Expressing, MANN-WHITNEY

Therapeutic activity of PBC-relevant pMHCII-NPs can be suppressed by IL-10 and TGFβ blockade. a Percentages of tetramer+CD4+ T cells in blood and lymphoid organs of NOD. c3c4.scid hosts reconstituted with whole splenocytes from untreated NOD. c3c4 donors a day after transfusion with splenic CD4+ T-cells from untreated or PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice. The hosts were either left untreated or were treated with PDC 166–181 /IA g7 -NPs. b Representative FACS staining histograms (left) and average mean fluorescence intensity values for TR1 markers on tetramer+CD4+ vs. tetramer−CD4+ T-cells (right) of the hosts treated with PDC 166–181 /IA g7 -NPs. c and d Macroscopic scores and liver weights ( c ) and microscopic scores ( d ) of the mice studied in a . Data in a – d correspond to means ± SEM, were compared with Mann–Whitney U , and correspond to n = 9 (blue in c ) or 7 (blue in d ), 5 (red in a , c , and d ), and 5 mice (green in a , c , d )/treatment group, respectively. e Percentages of tetramer+ CD4+ T-cells in mice treated with pMHCII-NPs and rat-IgG (control) or blocking rat mAbs against mouse IL-10 or TGFβ. f – g Macroscopic ( f ) and microscopic ( g ) scores of the mice studied in a . Data in e – g correspond to n = 5, 3–4 and 4 mice/treatment group, respectively. h Macroscopic scores, liver weights, and microscopic scores of NOD. c3c4.scid hosts reconstituted with whole splenocytes from untreated NOD. c3c4 donors a day after transfusion of the hosts with: FACS-sorted splenic/PCLN-derived tetramer+CD4+ T-cells from PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice; purified PCLN B-cells from PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice; FACS-sorted splenic/PLN-derived tetramer+CD4+ T-cells from BDC2.5mi/IA g7 -NP-treated NOD; or purified PLN B-cells from BDC2.5mi/IA g7 -NP-treated NOD mice. Data in h correspond to n = 5/group (red, blue and yellow) or n = 4/group (orange and cyanine). Data in a – h correspond to mean ± SEM. P values were calculated via Mann–Whitney U

Journal: Nature Communications

Article Title: Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

doi: 10.1038/s41467-019-09893-5

Figure Lengend Snippet: Therapeutic activity of PBC-relevant pMHCII-NPs can be suppressed by IL-10 and TGFβ blockade. a Percentages of tetramer+CD4+ T cells in blood and lymphoid organs of NOD. c3c4.scid hosts reconstituted with whole splenocytes from untreated NOD. c3c4 donors a day after transfusion with splenic CD4+ T-cells from untreated or PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice. The hosts were either left untreated or were treated with PDC 166–181 /IA g7 -NPs. b Representative FACS staining histograms (left) and average mean fluorescence intensity values for TR1 markers on tetramer+CD4+ vs. tetramer−CD4+ T-cells (right) of the hosts treated with PDC 166–181 /IA g7 -NPs. c and d Macroscopic scores and liver weights ( c ) and microscopic scores ( d ) of the mice studied in a . Data in a – d correspond to means ± SEM, were compared with Mann–Whitney U , and correspond to n = 9 (blue in c ) or 7 (blue in d ), 5 (red in a , c , and d ), and 5 mice (green in a , c , d )/treatment group, respectively. e Percentages of tetramer+ CD4+ T-cells in mice treated with pMHCII-NPs and rat-IgG (control) or blocking rat mAbs against mouse IL-10 or TGFβ. f – g Macroscopic ( f ) and microscopic ( g ) scores of the mice studied in a . Data in e – g correspond to n = 5, 3–4 and 4 mice/treatment group, respectively. h Macroscopic scores, liver weights, and microscopic scores of NOD. c3c4.scid hosts reconstituted with whole splenocytes from untreated NOD. c3c4 donors a day after transfusion of the hosts with: FACS-sorted splenic/PCLN-derived tetramer+CD4+ T-cells from PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice; purified PCLN B-cells from PDC 166–181 /IA g7 -NP-treated NOD. c3c4 mice; FACS-sorted splenic/PLN-derived tetramer+CD4+ T-cells from BDC2.5mi/IA g7 -NP-treated NOD; or purified PLN B-cells from BDC2.5mi/IA g7 -NP-treated NOD mice. Data in h correspond to n = 5/group (red, blue and yellow) or n = 4/group (orange and cyanine). Data in a – h correspond to mean ± SEM. P values were calculated via Mann–Whitney U

Article Snippet: Synthetic PDC-E2 166–181 and 2.5mi peptides were purchased from Genscript (Piscataway, NJ).

Techniques: Activity Assay, Staining, Fluorescence, MANN-WHITNEY, Control, Blocking Assay, Derivative Assay, Purification

Liver-specific regulatory network formation. a Cytokine profile of LPS-challenged CD11b+ cells from PCLNs and MLNs. b Cytokine profile of Kupffer cells (only statistically significant analytes shown in a and b ) ( n = 3/group). c Absolute numbers of B-cells (top) and tetramer+ T-cells (bottom) in PCLNs, ILNs, and liver. Data for B-cells correspond to n = 15 and 19 (PCLN), n = 11 and 11 (ILN), and n = 12 and 16, respectively (liver), from 3–5 experiments/organ. Data for tetramer+ cells correspond to n = 14 and 19 (PCLN), n = 11 and 11 (ILN), and n = 15 and 16, respectively (liver), from 3–5 experiments/organ. d Correlation between numbers of B-cells and tetramer+ cells in the PCLNs, liver, and ILNs of PDC 166–181 /IA g7 -NP-treated mice ( n = 19, 16 and 11; 4, 5 and 3 experiments, respectively). e IL-10 secretion by LPS-challenged B-cells from PCLNs, MLNs, and liver ( n = 4 and 3 mice/treatment type, respectively). f Representative FACS plots showing conversion of eGFP– B cells from NOD. Il10-eGFP donors into eGFP+/CD5+/CD1d hi Bregs in PDC-E2 166–181 /IA g7 -NP-treated hosts. g Percentages of B cell-to-Breg cell conversion in PDC-E2 166–181 /IA g7 -NP vs. Cys-NP-treated NOD. c3c4 hosts, in liver, spleen, PCLNs, and MLNs ( n = 3 and 4 mice/treatment type, respectively). h Percentages of B cell-to-Breg cell conversion in PDC-E2 166–181 /IA g7 -NP-treated NOD. c3c4 hosts, in spleen, PCLNs, and MLNs, as a function of the peptide displayed on the B-cell surface (non-cognate: BDC2.5mi, n = 4/organ; or cognate: PDC 166–181 , n = 3/organ). Data correspond to mean ± SEM. P values were calculated via multiple t-test analysis ( a and b ), Mann–Whitney U ( c , e , g and h ) or Pearson’s correlation test ( d )

Journal: Nature Communications

Article Title: Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

doi: 10.1038/s41467-019-09893-5

Figure Lengend Snippet: Liver-specific regulatory network formation. a Cytokine profile of LPS-challenged CD11b+ cells from PCLNs and MLNs. b Cytokine profile of Kupffer cells (only statistically significant analytes shown in a and b ) ( n = 3/group). c Absolute numbers of B-cells (top) and tetramer+ T-cells (bottom) in PCLNs, ILNs, and liver. Data for B-cells correspond to n = 15 and 19 (PCLN), n = 11 and 11 (ILN), and n = 12 and 16, respectively (liver), from 3–5 experiments/organ. Data for tetramer+ cells correspond to n = 14 and 19 (PCLN), n = 11 and 11 (ILN), and n = 15 and 16, respectively (liver), from 3–5 experiments/organ. d Correlation between numbers of B-cells and tetramer+ cells in the PCLNs, liver, and ILNs of PDC 166–181 /IA g7 -NP-treated mice ( n = 19, 16 and 11; 4, 5 and 3 experiments, respectively). e IL-10 secretion by LPS-challenged B-cells from PCLNs, MLNs, and liver ( n = 4 and 3 mice/treatment type, respectively). f Representative FACS plots showing conversion of eGFP– B cells from NOD. Il10-eGFP donors into eGFP+/CD5+/CD1d hi Bregs in PDC-E2 166–181 /IA g7 -NP-treated hosts. g Percentages of B cell-to-Breg cell conversion in PDC-E2 166–181 /IA g7 -NP vs. Cys-NP-treated NOD. c3c4 hosts, in liver, spleen, PCLNs, and MLNs ( n = 3 and 4 mice/treatment type, respectively). h Percentages of B cell-to-Breg cell conversion in PDC-E2 166–181 /IA g7 -NP-treated NOD. c3c4 hosts, in spleen, PCLNs, and MLNs, as a function of the peptide displayed on the B-cell surface (non-cognate: BDC2.5mi, n = 4/organ; or cognate: PDC 166–181 , n = 3/organ). Data correspond to mean ± SEM. P values were calculated via multiple t-test analysis ( a and b ), Mann–Whitney U ( c , e , g and h ) or Pearson’s correlation test ( d )

Article Snippet: Synthetic PDC-E2 166–181 and 2.5mi peptides were purchased from Genscript (Piscataway, NJ).

Techniques: MANN-WHITNEY